---
schema_version: "secwatch.filing_event.v1"
accession: "0001091818-26-000084"
form_type: "8-K"
ticker: "BFNH"
cik: "0001310488"
company_name: "BIOFORCE NANOSCIENCES HOLDINGS, INC."
filed_at: "2026-06-18T12:28:29+00:00"
generated_at: "2026-06-18T12:30:07.642618+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# BioForce Nanosciences changes control; sells 79.65% stake; pivots to oil & gas

## Summary
- Merle Ferguson sold 26.7M shares (79.65% of outstanding) to Nexus Capital Investments for $400,000 on April 15, 2026.
- Co-CEOs Steven Gagnon and John LaViolette, and VP Sasha Shapiro resigned effective June 17, 2026.
- Scott Mager appointed as Director effective June 15, 2026; Richard Kaiser named interim CEO.
- Company shifts business from vitamin supplements to oil and gas industry; evaluating opportunities.

## SEC filing metadata
- accession: 0001091818-26-000084
- form_type: 8-K
- ticker: BFNH
- cik: 0001310488
- company_name: BIOFORCE NANOSCIENCES HOLDINGS, INC.
- filed_at: 2026-06-18T12:28:29+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 5.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/0001091818-26-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/bfnh-06182026_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001091818-26-000084
- JSON: https://secwatch.observer/filing/0001091818-26-000084.json
- Plain text: https://secwatch.observer/filing/0001091818-26-000084.txt

## Key facts
- Executive change
  Richard Kaiser was appointed as interim Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
  - Action: appointed
  - Role: interim Chief Executive Officer
  source text: On June 17, 2026, the Company’s Board of Directors appointed Richard Kaiser as the Company’s interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/0001091818-26-000084-index.htm
- Executive change
  John LaViolette resigned as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
  - Action: resigned
  - Role: Co-Chief Executive Officer
  source text: On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/0001091818-26-000084-index.htm
- Executive change
  Scott Mager was appointed as Director at BIOFORCE NANOSCIENCES HOLDINGS, INC..
  - Action: appointed
  - Role: Director
  source text: Effective June 15, 2026, the Board of Directors appointed Scott Mager as Directors of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/0001091818-26-000084-index.htm
- Executive change
  Steven Gagnon resigned as Co-Chief Executive Officer at BIOFORCE NANOSCIENCES HOLDINGS, INC..
  - Action: resigned
  - Role: Co-Chief Executive Officer
  source text: On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/0001091818-26-000084-index.htm
- Executive change
  Sasha Shapiro resigned as Vice-President at BIOFORCE NANOSCIENCES HOLDINGS, INC..
  - Action: resigned
  - Role: Vice-President
  source text: On June 17, 2026, the Company’s Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.’s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company’s Vice-President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/0001091818-26-000084-index.htm
- M&A Transactions
  BIOFORCE NANOSCIENCES HOLDINGS, INC. underwent a change of control involving Nexus Capital Investments, Inc. for $400,000 (closed 2026-04-15).
  - Action: change of control
  - Counterparty: Nexus Capital Investments, Inc.
  - Consideration: $400,000
  - Closing: 2026-04-15
  source text: April 15, 2026, Merle Ferguson (“Seller”), a current Director of the Company sold 26,700,000 shares of his common stock in the Company to Nexus Capital Investments, Inc., a Delaware Corporation (“Purchaser”). This represented Mr. Ferguson’s controlling stock interest in the Company, equalling 79.65% of the outstanding common stock of the Company. Nexus Capital Investments, Inc. paid $400,000 to the Seller from its corporate funds; no loans were involved in this transaction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1310488/000109181826000084/0001091818-26-000084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.